Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomoki Naoe

Showing results (251-260 of 288) with videos related to

Pageof 29
Sort By:
International Journal of Hematology|April 27, 2017
Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 studyArinobu Tojo, Taiichi Kyo, Kazuhito Yamamoto, et al.
International Journal of Hematology|February 22, 2012
Dexamethasone palmitate successfully attenuates hemophagocytic syndrome after allogeneic stem cell transplantation: macrophage-targeted steroid therapySatoshi Nishiwaki, Takayuki Nakayama, Makoto Murata, et al.
Annals of Hematology|February 15, 2015
Chimerism status after unrelated donor bone marrow transplantation with fludarabine-melphalan conditioning is affected by the melphalan dose and is predictive of relapseNobuhiko Imahashi, Haruhiko Ohashi, Seitaro Terakura, et al.
Cancer Science|May 12, 2020
Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3-internal tandem duplication AML: The JALSG AML209-FLT3-SCT studyNaomi Kawashima, Yuichi Ishikawa, Yoshiko Atsuta, et al.
Blood|July 5, 2005
Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemiaTatsuya Suzuki, Hitoshi Kiyoi, Kazutaka Ozeki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2014
Tamibarotene as maintenance therapy for acute promyelocytic leukemia: results from a randomized controlled trialKatsuji Shinagawa, Masamitsu Yanada, Toru Sakura, et al.
Cancer Science|June 6, 2017
Phase II study of intrabone single unit cord blood transplantation for hematological malignanciesMakoto Murata, Yoshinobu Maeda, Masayoshi Masuko, et al.
International Journal of Hematology|May 19, 2009
A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALLArinobu Tojo, Kensuke Usuki, Akio Urabe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2007
Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patientsTakashi Oyama, Kazuhito Yamamoto, Naoko Asano, et al.
Blood Advances|July 5, 2024
Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 studyItaru Matsumura, Shigeki Ohtake, Yoshiko Atsuta, et al.
Pageof 29

Showing results (251-260 of 288) with videos related to

Sort By:
Pageof 29
International Journal of Hematology|April 27, 2017
Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 studyArinobu Tojo, Taiichi Kyo, Kazuhito Yamamoto, et al.
International Journal of Hematology|February 22, 2012
Dexamethasone palmitate successfully attenuates hemophagocytic syndrome after allogeneic stem cell transplantation: macrophage-targeted steroid therapySatoshi Nishiwaki, Takayuki Nakayama, Makoto Murata, et al.
Annals of Hematology|February 15, 2015
Chimerism status after unrelated donor bone marrow transplantation with fludarabine-melphalan conditioning is affected by the melphalan dose and is predictive of relapseNobuhiko Imahashi, Haruhiko Ohashi, Seitaro Terakura, et al.
Cancer Science|May 12, 2020
Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3-internal tandem duplication AML: The JALSG AML209-FLT3-SCT studyNaomi Kawashima, Yuichi Ishikawa, Yoshiko Atsuta, et al.
Blood|July 5, 2005
Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemiaTatsuya Suzuki, Hitoshi Kiyoi, Kazutaka Ozeki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2014
Tamibarotene as maintenance therapy for acute promyelocytic leukemia: results from a randomized controlled trialKatsuji Shinagawa, Masamitsu Yanada, Toru Sakura, et al.
Cancer Science|June 6, 2017
Phase II study of intrabone single unit cord blood transplantation for hematological malignanciesMakoto Murata, Yoshinobu Maeda, Masayoshi Masuko, et al.
International Journal of Hematology|May 19, 2009
A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALLArinobu Tojo, Kensuke Usuki, Akio Urabe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2007
Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patientsTakashi Oyama, Kazuhito Yamamoto, Naoko Asano, et al.
Blood Advances|July 5, 2024
Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 studyItaru Matsumura, Shigeki Ohtake, Yoshiko Atsuta, et al.
Pageof 29